blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2012586

EP2012586 - USES AND COMPOSITIONS FOR TREATMENT OF ANKYLOSING SPONDYLITIS [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  05.12.2014
Database last updated on 20.09.2024
Most recent event   Tooltip05.12.2014Withdrawal of applicationpublished on 07.01.2015  [2015/02]
Applicant(s)For all designated states
AbbVie Biotechnology Ltd
Clarendon House
2, Church Street
HM 11 Hamilton / BM
[2013/38]
Former [2009/03]For all designated states
Abbott Biotechnology Ltd.
Clarendon House 2 Church Street
Hamilton HM 11 / BM
Inventor(s)01 / WONG, Robert, L.
12 Riggs Court
Basking Ridge, NJ 07920 / US
02 / KUPPER, Hartmut
Lilienstrasse 43
67112 Mutterstadt / DE
03 / LUO, Michelle
1208 Virginia Ave.
Libertyville, IL 60048 / US
04 / SIEPER, Joachim
Bernerstrasse 21 A
12205 Berlin / DE
05 / MAKSYMOWYCH, Walter, P.
562 Heritage Medical Research Center, University of Alberta
Edmonton, Alberta T6G 252 / CA
06 / DAVIS, John
298 Juanity Way
San Francisco, CA 94127-1736 / US
07 / VAN DER HEIJDE, Desiree
Korte Raarberg 46
Meersen 6231 KR / NL
 [2009/03]
Representative(s)Modiano, Micaela Nadia, et al
Modiano Josif Pisanty & Staub Ltd
Thierschstrasse 11
80538 München / DE
[N/P]
Former [2009/36]Modiano, Micaela Nadia, et al
Modiano Josif Pisanty & Staub Ltd Thierschstrasse 11
80538 München / DE
Former [2009/03]Modiano, Micaela Nadia, et al
Modiano Josif Pisanty & Staub Ltd Thierschstrasse 11
80538 München / DE
Application number, filing date07755151.310.04.2007
[2009/03]
WO2007US08787
Priority number, dateUS20060790909P10.04.2006         Original published format: US 790909 P
US20060809770P30.05.2006         Original published format: US 809770 P
US20060815489P20.06.2006         Original published format: US 815489 P
US20060858376P10.11.2006         Original published format: US 858376 P
US20070909683P02.04.2007         Original published format: US 909683 P
[2009/03]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2007120626
Date:25.10.2007
Language:EN
[2007/43]
Type: A2 Application without search report 
No.:EP2012586
Date:14.01.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 25.10.2007 takes the place of the publication of the European patent application.
[2009/03]
Search report(s)International search report - published on:US23.10.2008
(Supplementary) European search report - dispatched on:EP16.07.2010
ClassificationIPC:A61K39/395
[2010/27]
CPC:
C07K16/241 (EP,US); A61K49/0004 (US); A61K2039/505 (EP,US);
A61K2039/545 (US); C07K2317/21 (EP,US); C07K2317/565 (US);
C07K2317/92 (US) (-)
Former IPC [2009/03]A01N37/18, C07K1/00, C07K16/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/03]
Extension statesBA10.11.2008
HR10.11.2008
MK10.11.2008
RS10.11.2008
TitleGerman:ANWENDUNGEN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON MORBUS BECHTEREW[2009/03]
English:USES AND COMPOSITIONS FOR TREATMENT OF ANKYLOSING SPONDYLITIS[2009/03]
French:UTILISATIONS ET COMPOSITIONS POUR LE TRAITEMENT DE LA SPONDYLARTHRITE ANKYLOSANTE[2009/03]
Entry into regional phase10.11.2008National basic fee paid 
10.11.2008Search fee paid 
10.11.2008Designation fee(s) paid 
10.11.2008Examination fee paid 
Examination procedure09.11.2007Request for preliminary examination filed
International Preliminary Examining Authority: US
10.11.2008Examination requested  [2009/03]
14.02.2011Amendment by applicant (claims and/or description)
09.06.2011Despatch of a communication from the examining division (Time limit: M06)
19.12.2011Reply to a communication from the examining division
31.01.2013Despatch of a communication from the examining division (Time limit: M06)
12.08.2013Reply to a communication from the examining division
24.11.2014Cancellation of oral proceeding that was planned for 25.11.2014
25.11.2014Date of oral proceedings (cancelled)
26.11.2014Application withdrawn by applicant  [2015/02]
Divisional application(s)EP13172513.7  / EP2708242
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  09.06.2011
Fees paidRenewal fee
07.04.2009Renewal fee patent year 03
15.03.2010Renewal fee patent year 04
06.04.2011Renewal fee patent year 05
21.03.2012Renewal fee patent year 06
26.03.2013Renewal fee patent year 07
26.03.2014Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]US2005249735  (LE JUNMING [US] ET AL) [A] 1,3,6-9 * the whole document *;
 [X]  - HAIBEL HILDRUN ET AL, "Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.", ARTHRITIS AND RHEUMATISM FEB 2006 LNKD- PUBMED:16447247, (200602), vol. 54, no. 2, ISSN 0004-3591, pages 678 - 681, XP002583872 [X] 1,3,6-9 * the whole document *

DOI:   http://dx.doi.org/10.1002/ART.21563
 [X]  - HAIBEL H ET AL, "Adalimumab in the treatment of active ankylosing spondylitis: Results of an open-label, 52-week trial", ANNALS OF THE RHEUMATIC DISEASES, & ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY; VIENNA, AUSTRIA; JUNE 08 11, 2005, (200507), vol. 64, no. Suppl. 3, ISSN 0003-4967, page 316, XP009133948 [X] 6-9 * the whole document *
 [X]  - M03-606 STUDY GRP, "Efficacy of adalimumab in active ankylosing spondylitis (AS) - Results of the Canadian AS study", ARTHRITIS & RHEUMATISM, & 69TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOG Y/40TH ANNUAL SCIENTIFIC MEETIN; SAN DIEGO, CA, USA; NOVEMBER 12 -17, 2005, (200509), vol. 52, no. 9, Suppl. S, ISSN 0004-3591, page S217, XP009133939 [X] 6-9 * the whole document *
 [X]  - DAVIS J ET AL, "Major clinical response and partial remission in ankylosing spondylitis subjects treated with adalimumab: The ATLAS trial.", ARTHRITIS & RHEUMATISM, & 69TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOG Y/40TH ANNUAL SCIENTIFIC MEETIN; SAN DIEGO, CA, USA; NOVEMBER 12 -17, 2005, (200509), vol. 52, no. 9, Suppl. S, ISSN 0004-3591, pages S208 - S209, XP009133946 [X] 6-9 * the whole document *
 [X]  - ATLAS STUDY GRP, "Adalimumab therapy results in significant reduction of signs and symptoms in subjects with Ankylosing spondylitis: The ATLAS trial.", ARTHRITIS & RHEUMATISM, & 69TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOG Y/40TH ANNUAL SCIENTIFIC MEETIN; SAN DIEGO, CA, USA; NOVEMBER 12 -17, 2005, (200509), vol. 52, no. 9, Suppl. S, page S281, XP009133984 [X] 6-9 * the whole document *
 [X]  - VAN DER HEIJDE D ET AL, "Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis - The ATLAS trial.", ARTHRITIS & RHEUMATISM, & 69TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY/40TH ANNUAL SCIENTIFIC MEETING; SAN DIEGO, CA, USA; NOVEMBER 12 -17, 2005, (200509), vol. 52, no. 9, Suppl. S, ISSN 0004-3591, page S211, XP002584157 [X] 6-9 * the whole document *
 [X]  - LUC MATHIEU ET AL, "Patients without biological inflammation are responders to anti-TNF-alpha in axial ankylosing spondylitis", ARTHRITIS & RHEUMATISM, & 69TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOG Y/40TH ANNUAL SCIENTIFIC MEETIN; SAN DIEGO, CA, USA; NOVEMBER 12 -17, 2005, (200509), vol. 52, no. 9, Suppl. S, ISSN 0004-3591, page S216, XP009133940 [X] 6-9 * the whole document *
 [A]  - BOULOS PAULINE ET AL, "Pharmacological treatment of ankylosing spondylitis: a systematic review.", DRUGS 2005 LNKD- PUBMED:16225367, (2005), vol. 65, no. 15, ISSN 0012-6667, pages 2111 - 2127, XP009133932 [A] 1,3,6-9 * the whole document *
 [A]  - DAVIS J C, "Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis", SEMINARS IN ARTHRITIS AND RHEUMATISM,, (20050201), vol. 34, no. 4, ISSN 0049-0172, pages 668 - 677, XP004732603 [A] 1,3,6-9 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.semarthrit.2004.08.005
 [A]  - WENDLING DANIEL ET AL, "Anti-TNF-alpha therapy in ankylosing spondylitis.", EXPERT OPINION ON PHARMACOTHERAPY JUL 2004 LNKD- PUBMED:15212600, (200407), vol. 5, no. 7, ISSN 1465-6566, pages 1497 - 1507, XP009133938 [A] 1,3,6-9 * the whole document *
 [A]  - EFTHIMIOU P ET AL, "ROLE OF BIOLOGICAL AGENTS IN IMMUNE-MEDIATED INFLAMMATORY DISEASES", SOUTHERN MEDICAL JOURNAL, SOUTHERN MEDICAL ASSOCIATION, US LNKD- DOI:10.1097/01.SMJ.0000153119.37032.8B, (20050201), vol. 98, no. 2, ISSN 0038-4348, pages 192 - 204, XP009063672 [A] 1,3,6-9 * the whole document *

DOI:   http://dx.doi.org/10.1097/01.SMJ.0000153119.37032.8B
 [A]  - BRAUN J ET AL, "BIOLOGIC THERAPIES IN THE SPONDYLOARTHRITIS: NEW OPPORTUNITIES, NEW CHALLENGES", CURRENT OPINION IN RHEUMATOLOGY, CURRENT SCIENCE, LONDON, GB LNKD- DOI:10.1097/00002281-200307000-00005, (20030701), vol. 15, no. 4, ISSN 1040-8711, pages 394 - 407, XP008019243 [A] 1,3,6-9 * the whole document *

DOI:   http://dx.doi.org/10.1097/00002281-200307000-00005
International search[Y]WO9729131  (Salfeld) [Y] 20-23, 55-58, 62-65 * . See throughout. *
 [X]  - CHEROUVIM E.P. et al., "Infliximab therapy for patients with active and refractory spodylarhropathies at the dose of 3 mg/kg.", J. Clin. Rheumatol., (20040801), vol. 10, pages 162 - 168, XP008130677 [X] 1-5, 7-19, 24-54, 59-61 6, 20-23, 55-58, 62-65 * . See throughout. *
 [Y]  - DE KEYSER et al., "Anti-TNF-alpha therapy in ankylosing spondylitis.", Cytokine., vol. 93, pages 294 - 298, XP008130678 [Y] 23, 58, 65 * . See Abstract. *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.